PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The Rise in Disease Incidence Rate Boosts Demand for Innovative Therapeutics Finds Frost & Sullivan - The need for Cardiovascular Drug-Discoveries
The Rise in Disease Incidence Rate Boosts Demand for Innovative Therapeutics Finds Frost & Sullivan


NewswireToday - /newswire/ - London, United Kingdom, 2012/02/24 - The need for Cardiovascular Drug-Discoveries.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Changing lifestyles, hectic day-to-day activities and unhealthy eating habits have been on the rise over the last decade, directly impacting the health of every individual. These trends prevail in varied proportions across the entire global population. Additionally, the strong prevalence of unhealthy conditions like obesity gives rise to several health-related complications. All these factors directly contribute toward the rise in drug discoveries.

They key to developing a drug is to essentially understand the nature of the disease for which it is being developed, disease symptoms and its reaction to chemical compounds present. The process is time-consuming and expensive; however, it is the first step toward drug discovery.

"Over the past decade, pharmaceutical companies have made tremendous progress in presenting drugs for the treatment of coronary heart disease, thromboembolism, myocardial infarction, ischemic stroke and hypertension," explains Deepika Pramod Chopda, Research Associate at Frost & Sullivan. "According to the Pharmaceutical Research and Manufactures of America (PhRMA) and the European Medicines Agency (EMA), around 300 different drugs across the aforementioned categories have been developed."

Innovative drug therapies, combination drugs and improvised drug delivery mechanisms form the basis of most of the new research in this disease category. In recent times, researchers have been concentrating on understanding a diseased cardiovascular condition from a molecular level. Genomics, proteomics and the use of computational power represent new ways of understanding unhealthy conditions.

New drugs are aimed at treating existing disease symptoms besides preventing new cardiovascular disorders. Improvised technologies and innovative scientific approaches have been extensively employed in developing new products. Screening tools have extensively been developed to enable research to perform work in a short span of time.

The rise in the number of therapy options reflects the developments made in the entire cardiovascular segment. An increase in the number of orphan drug approvals has also been observed in the recent past. These achievements are made by the tremendous backing of the advances in science and technologies. Significant developments in the field of molecular genetics and advancements in the stem cell space have created opportunities to explore the rare and complicated conditions of this therapeutic segment.

Growing investments in research and development by a large number of organisations have further helped in the introduction of new treatment products. Innovative concepts acquired from the field of life sciences, like the use of molecular antibodies, have led to the use of live cells for therapies. The concept of combining biology with pharmaceuticals, as practised by biopharmaceutical companies, has been on the rise as a measure to generate new and improvised treatment alternatives. Technologies are also being developed to use automation and robotics for new drug identification.

For the population at large, a strong understanding of the prescribed treatment methods, and adherence to the same, will serve as potential lifesavers. Enhanced awareness also helps patients reduce the odds of experiencing life-threatening situations by taking the necessary precautions. "In addition to the aforementioned efforts, the importance of following and completing the course of treatment is equally essential," concludes Deepika Pramod Chopda. "The rise in awareness will help in improving the quality of care and precautions to be taken for cardiovascular diseases."

If you would like to know more about Cardiovascular Drug-Discoveries, please send an email with your full contact details to Janique Morvan, Corporate Communications, at janique.morvan[.]

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

The Rise in Disease Incidence Rate Boosts Demand for Innovative Therapeutics Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Janique Morvan 
+33(0)1 42 81 20 37 janique.morvan[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (